The Latin American and Caribbean Medical Confederation (CONFEMEL), an organization that brings together related organizations from countries of the region, works on behalf of the medical profession and the population's health guided by international documents. During its General Assembly (Pachuca, Mexico; the Declaration of Pachuca was approved with strong critics regarding the review of the Declaration of Helsinki that occurred in Brazil and the issue of clinical trials that use placebo in diseases with known treatment. The strong and energetic tone of this Declaration proposes that member entities condemn ethical abuses in all forums and also to administrations so that they engage against the use of placebo in these conditions. These recommendations are supported in the global movement on Integrity and Ethics in Research. The conclusion addresses the importance of the educative role of ethical supervision of Medicine warning physicians who violate these guidelines, which are also incorporated in the Code of Medical Ethics, that they will be subjected to ethical-professional process. Keywords: Placebo. Declaration of Helsinki. Medicine. Biomedical research. Medical legislation. Integrity in research.
The placebo and the Declaration of Pachuca: dead letters?
The Confemel
The federal councils and medical colleges of Latin American and Caribbean countries created, in 1997, the Medical Confederation of Latin American and the Caribbean (Confemel), a non-governmental medical entity, nonprofit, with the objective, among others, o act in favor of the health of the populations, from the human, scientific, technological and political perspectives. The Confemel is governed by the principles of universality, comprehensiveness, equity and accessibility, that is, has as its premises that medical attention must be universal, comprehensive, equitable and egalitarian, providing access opportunity with quality and cordiality. Furthermore, its action is guided by several international documents, including the Declaration of Helsinki (DoH), from 1964, modified in Scotland in 2000 1 . The confederation brings together medical organizations from 19 countries in the region, including the six that more conducted clinical trials in Latin America, as recorded in the international platform clinicaltrial.gov: Brazil, Mexico, Argentina, Chile, Colombia and Peru. In Brazil's party, three national medical entities integrated Confemel: the Federal Medical Council, the Brazilian Medical Association and the National Federation of Physicians.
The Confemel annually gathers in a general meeting, when deliberations are taken on acute issues of human health that affect people and physicians in the region. Thus, in its 11 th Ordinary Annual Meeting, in 2008, the Declaración de Buenos Aires sobre Investigaciones Médicas (Declaration on Medical Investigations of Buenos Aires), with tough criticism about the DoH changes introduced in the same year in Seoul, South Korea, by the World Medical Association (WMA), especially in relation to the double standard, and in which concludes its strong commitment to act on governments of countries that are part of it, to prevent its implementation 2 . The last of these meetings, the 16 th in its history of struggles and advances occurred in the Mexican city of Pachuca, in November 2013, when it was discussed a controversial topic, antique, but still current, related to the use of placebo as control in clinical trials.
The placebo and the Helsinki Declaration of 2013 -Fortaleza, Ceará, Brazil
The subject of the 16 th meeting concerned, specifically, an episode from a month earlier in Fortaleza, Ceará, Brazil, when the WMA approved a new Declaration of Helsinki (DoH 2013) 3 , whose text on the use of placebo inadequately became more flexible. In turn, the Declaration of Pachuca was approved as follows: unanimously rejects any medical research involving human subjects using a placebo when there is a proven medication for the condition under study. The poor and vulnerable populations, discriminated by their lack of resources can not be subjected to biomedical research that have lower security levels to those applied in societies of greater development 4 
.
The document, by criticizing the DoH 2013, approved in Brazil, also notes that: c) In terms of point 33, the use of placebo when there are proven and effective interventions is contrary to principles and values of the profession and medical ethics. [...] e) As immediate it proposes to the respective governments not authorizing no financial support for medication that has used placebo, when existing better proven interventions. f) The member Associations commit to denounce this situation in all instances and national and international forums, as well as in their governments, and to promote institutional actions from CONFEMEL to impede the application of this norm inn the medical investigation 4 .
It is important to emphasize the strong revolt of the supervisory bodies of medical practice in Latin America and the Caribbean on the flexibilization of the use of placebo included in DoH 2013, to the point to, for the first time, propose that governments do not allow trials with this ethical bias and that this situation is denounced at all levels of government to prevent its application in our territory.
The leadership of Brazil and the role of the Federal Council of Medicine on the ethical use of placebo
The Brazil, while ago, has the recognition of the national and international community connected to the DoH, in particular by its strong and permanent performance of the Federal Council of Medicine (FCM) in defending the ethical use of placebo 6 . In Brazil, the WMA always found acceptance of the DoH as the FCM was the first national organization to support it, transforming its guidelines on a professional ethics norm to be followed by the medical category under its jurisdiction in respect of 
The use of placebo and the disregard for ethical standards in Brazil
However, despite the duration of the CEM and other ethical standards, it seems that some medical researchers insist to ignore them and continue to use placebo in diseases for which there is a huge range of effective drugs available. In a survey of the clinical trials phase III drugs for any disease, and registered in clinicaltrials.gov platform for ten years, being five before and five after 2008, it was concluded by the ineffectiveness of ethical constraints determined by the FCM, as well as those contained from the resolutions of the National Health Council (CNS), given that the placebo percentage usage, when comparing the two periods was similar and that in studies with sponsorship of university institutions, national companies and others, there was a significant increase after 2008 13 .
Most decisive example of the failure to comply with the CEM was observed in phase III clinical trials in patients with type 2 diabetes, registered in clinicaltrials.gov, sponsored by the pharmaceutical industry and which in 51.6% (93/48) of the studies conducted in Brazil, between 2003 and 2013, placebo was used as control arm. Needless to emphasize the range of drugs available for the treatment of this disease, and yet, in more than half of the studies, the control-arm contained placebo, which sets ethical infraction. Unimaginable that this is happening with Brazilian participants, who should also be equally supported by the resolutions of the National Health Council.
These data were collected in the cited online platform, in where it was possible to obtain the total intervention by drugs in diabetes 2 in the reference period by the insertion of descriptors in Find Studies and Advanced Search icons: "drug"; "excluded Unknown"; "Interventional Studies"; "diabetes 2"; "Brazil"; "Child, Adult, Senior"; "Phase 3"; "Industry"; "received from 01/01/2003 to 31/12/2013." In turn, to obtain the number of such tests with placebo, this word was inserted in the same Advanced Search and Find Studies icons, "drug"; "Excluded Unknown"; "Interventional Studies"; "2 diabetes"; "Placebo"; "Brazil"; "Child, Adult, Senior"; "Phase 3"; "Industry"; "Received from 1/1/2003 to 31/12/2013."
It is also alerted that research in diabetes, due to the chronic course of the disease, presents several years of use of placebo in the control arm. The data from these surveys of clinicaltrials. As it is known, studies sponsored by multinational industries have their protocols developed abroad, being up to the specialist physicians in Brazil to accept or not to participate when asked. By these numbers, it seems that many agree to participate as [17] [18] [19] . One of them 19 , expanding its indignation against the 2013DoH, proposed that Latin America abandons the DoH and creates its own ethical document, facing our reality.
Nothing illogical in this proposal, if we considere that the United States, through the Food and Drug Administration (FDA) abandoned the DoH in October 2008, replacing it with the Good Clinical Practices/International Conference on Harmonization (GCP/ICH), 1996 . As known, this document is intended to harmonize the methodological procedures between the US, Europe and Japan, to facilitate the mutual acceptance of clinical trials by its regulatory agencies 18 , not being, therefore, an ethical document, reason why it can not be a substitute for the DoH. However, by addressing a specific field of professional ethics of the researcher, nothing more logical that the subject to be included in the range of ethical codes from the various health professions, by involving ethical values as beneficence, the non-maleficence, recklessness and the negligence, directly related to the use of placebo in clinical trials. Add to them the principle of justice, since everyone in-The placebo and the Declaration of Pachuca: dead letters? volved in the study should be offered the same rights of access to the best possible treatments.
In that regard, it is interessing the journal's editorial of the Brazilian Medical Association 26 , that by treating the placebo use, states that the therapeutic concealment, in principle, will bring no direct benefit to those using it and questions the reason why the physician would include in his study patients that will not get direct benefit of the research. The editorial also suggests that, in the event of damage to the patient using placebo, it is possible that there was recklessness or negligence on the part of the professional, because doctors know the risks of using placebo in diseases whose treatment is known.
In this case, one can assume that the physician would be infringing the Code of Medical Ethics (CME), which in its Article 1 st of Chapter III, which deals with the professional responsibility of the CEM, seals: Causing harm to the patient, by act or omission, characterized as malpractice, recklessness or negligence. Besides, would certainly be also disrespecting Article 106, which prohibits the physician: Keep relationship of any nature with medical research involving human subjects, that use placebo in their experiments, when there is efficient and effective treatment for the disease researched 11 .
The ethical sanction in this case would seek to maintain the high ethical standards of medicine, with respect and defend the rights of patients, the sole and true reason for belonging to medicine. On the other hand, in where the clear ethical infraction by Brazilian physicians who participate in clinical trials involving the use of placebo in the treatments of recognized diseases, what is known, there is no record of any denunciation or establishment of ethical-professional process by not respecting the care in the use of placebo in regional or federal councils of Medicine. The actions of the researcher that, by intention or negligence, contradict these assumptions represent an ethically improper conduct from the point of view of research integrity 25 . In other words, in tests involving the use of placebo in clear disregard of national and international standards, it can be consider that the researcher and the sponsors of these studies are making a mistake that, besides being unethical, can be classified as not righteous conduct.
Thus, it appears that there is a perfect interaction of the Declaration of Pachuca terms with the theme of integrity and ethics in research. In Brazil, besides the two BRISPE, it happened, for the first time, the formal manifestation of the Nation- 28 . It is hence understood that the deliberate and conscious use of placebo in clinical trials in the above situations can be considered scientific misconduct by disregard of ethical standards identified above.
In continuation to this educational process, Spink 29 , in an insightful analysis on ethics in scientific research, points out that the first challenge to be faced arises from the increasing subordination of science to powerful private economic groups, which have the means to guide their results as their interests. The author cites, among others, that the use of vulnerable populations in clinical trials is related to the growing concern about ethical issues in science. This is a frequent practice in trials conducted in Brazil 9 .
Final Considerations
Given the orientation of the Declaration of Pachuca that their affiliated institutions should act more strictly to prevent the conduct of clinical trials with placebo ethically unjustifiable, it is expected that -if this directive is put into practice by the institutions that signed it, as is the case of entities in Brazil -from now, the current situation of scientific freedom, but of questionable ethical conduct, will be monitored, and the physicians better oriented.
It is believed that the range of activities may place these actions in three levels of the medical field: a) educational activities, with the implementation of preventive and educational measures to be started with researchers, academic and clinical research centers in the country, either by events, standards or other similar activities; b) enforcement actions in clinical research centers; c) discourage actions to theunethical use of placebo, including
opening of ethical and disciplinary proceedings, if it is the case.
The first one should be the most feasible and easier, given the many mechanisms of access to physicians, either through e-mail, newsletters, magazines and other forms. However, to develop the second level of action, it is nnecessary to refer to the recent FCM Resolution 2.056/2013, which establishes criteria for the authorization of medical services operation of any nature and establishes a minimum criteria for its ethical operation 30 .
In addition, the FCM Resolution 2.056/2013 assigns to medical directors invested in administrative functions the co-responsibility, when properly aware, if the practice of medicine is in disagreement with this standard. 
